Comparison of Treatment Outcomes among Sibling Oocytes Using Different Culture Systems—Conventional IVF versus INVOcell Device—And Evaluation of INVOcell User Satisfaction: The INVOcIVF Study

Wan Syahirah Yang Mohsin, Nor Shaireen Abdullah Chue, Fazilah Abdul Hamid, Muhammad Azrai Abu, Sukhilmi Othman, Norazilah Mat Jin, Shu Yuan Woon, Abdul Kadir Abdul Karim and Mohd Faizal Ahmad ()
Additional contact information
Wan Syahirah Yang Mohsin: Advanced Reproductive Centre HCTM Cheras, Kuala Lumpur 56000, Malaysia
Nor Shaireen Abdullah Chue: Advanced Reproductive Centre HCTM Cheras, Kuala Lumpur 56000, Malaysia
Fazilah Abdul Hamid: Advanced Reproductive Centre HCTM Cheras, Kuala Lumpur 56000, Malaysia
Muhammad Azrai Abu: Advanced Reproductive Centre HCTM Cheras, Kuala Lumpur 56000, Malaysia
Sukhilmi Othman: Hospital Bersalin Sukhilmi, No. 1-G, Jalan Coco Drive 3, Taman Bandar Senawang, Senawang 70450, Malaysia
Norazilah Mat Jin: Advanced Reproductive Centre HCTM Cheras, Kuala Lumpur 56000, Malaysia
Shu Yuan Woon: Advanced Reproductive Centre HCTM Cheras, Kuala Lumpur 56000, Malaysia
Abdul Kadir Abdul Karim: Advanced Reproductive Centre HCTM Cheras, Kuala Lumpur 56000, Malaysia
Mohd Faizal Ahmad: Advanced Reproductive Centre HCTM Cheras, Kuala Lumpur 56000, Malaysia

IJERPH, 2022, vol. 19, issue 19, 1-11

Abstract: INVOcell is considered an alternative to conventional IVF proposed for intravaginal embryo culture; however, implementation is still low because evidence is scanty regarding its outcome and, most importantly, the device’s user satisfaction. Thus, we aim to compare the embryo outcome of sibling oocytes following INVOcell culture with conventional IVF (cIVF) by assessing its clinical outcome (fertilization, blastulation rate, and good embryo quality) and the user satisfaction evaluation based on a local validation questionnaire. A prospective study was done at a university-setting hospital for 12 months (July 2021–2022). The oocytes collected were divided into INVOcell and cIVF groups equally. Inclusion criteria included <40 years old and body mass index (BMI) < 30 kg/m 2 . The pre- and post-satisfaction questionnaires were assessed. In total, 23 women were included following standard controlled ovarian stimulation (COS). The mean age was 32.9, and the mean BMI was 24.9 kg/m 2 . Most of them suffered from tubal factors. A total of 252 oocytes were collected and incubated accordingly (cIVF; 138, INVOcell; 114). The blastulation rate was superior in the INVOcell group ( p = 0.16); otherwise, the fertilization rate and good embryo quality were not significantly different between both methods ( p > 0.05). Overall, women were satisfied with the INVOcell device as they were adequately advised, follow-up was scheduled, and the lowest score was obtained for all side effects of the device. Although both methods produce similar fertilization rates and good-quality embryos, the blastulation rates were better in the INVOcell group. Functionally, it is a user-friendly device and tolerable. Therefore, INVOcell can be used as an alternative method for reproductive treatment in carefully selected patients without jeopardizing the IVF outcomes.

Keywords: in vitro fertilization; intravaginal culture; INVOcell; blastulation; fertilization; user satisfaction; quality of life (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/19/12391/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/19/12391/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:19:p:12391-:d:928734

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().